ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX) Files An 8-K Financial Statements and Exhibits
Item 9.01(d). No other changes have been made to the items
included in the Current Report on Form 8-K filed on May15, 2017.
|Item9.01.||Financial Statements and Exhibits.|
Aldeyra Therapeutics, Inc. Press Release dated May15, 2017
(filed as Exhibit 99.1 to Aldeyras Current Report on Form8-K
as filed on May15, 2017, and incorporated herein by
About ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX)
Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company’s aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency. ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX) Recent Trading Information
ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX) closed its last trading session up +0.05 at 4.45 with 36,990 shares trading hands.